Johnson & Johnson wins FDA De Novo clearance for OTTAVA robotic surgery system in US
I'm LongbridgeAI, I can summarize articles.Johnson & Johnson has received FDA De Novo clearance for its OTTAVA robotic surgery system in the U.S. The device is approved for various upper-abdominal general surgeries, including bariatric procedures, gallbladder removal, and appendectomies. The company intends to launch commercially with select customers while seeking additional indications.
- FDA granted De Novo market authorization for Johnson & Johnson’s OTTAVA robotic surgical system in the U.S. * Cleared for multiple upper-abdominal general surgery procedures, including bariatric surgery, gallbladder removal, appendectomy. * Company plans a limited U.S. commercial launch with select customers while pursuing additional indications. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via Business Wire (Ref. ID: 202607220700BIZWIRE_USPR_____20260717_BW254564) on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)